MCRB - Why Is Microbiome-Based Seres Therapeutics Stock Trading Higher Today? | Benzinga
Seres Therapeutics Inc (NASDAQ: MCRB) received FDA Fast Track Designation for SER-155, an investigational oral, cultivated microbiome therapeutic designed to prevent GI-associated bacterial infections and to reduce the incidence of severe acute graft-versus-host disease in immunocompromised patients undergoing allogeneic hematopoietic stem cell transplantation.
- SER-155 Phase 1b Cohort 1 clinical data showed favorable tolerability, successful drug bacteria engraftment, and a substantial reduction in pathogen domination in the gastrointestinal microbiome, supporting progression to the placebo-controlled Cohort 2.
- SER-155 Phase 1b placebo-controlled Cohort 2 data readout is anticipated in the third quarter of 2024.
- Seres anticipates that ...